1. Most Discussed
  2. Gainers & Losers
BLT 2.0¢

Ann: GENERAL: BLT: New study- Effectiveness of BLIS M18 probiotic

    • Release Date: 02/02/15 08:30
    • Summary: GENERAL: BLT: New study- Effectiveness of BLIS M18 probiotic
    • Price Sensitive: No
    • Download Document  1.93KB
    02/02/2015 08:30
    REL: 0830 HRS BLIS Technologies Limited
    GENERAL: BLT: New study- Effectiveness of BLIS M18 probiotic
    Price sensitive announcement
    New study demonstrates effectiveness of BLIS M18TM probiotic
    February 1, 2015
    BLIS Technologies Ltd, Dunedin (BLT)
    BLT this week received advice of the publication of results of a new
    independent clinical trial of BLIS M18, a novel probiotic for the support of
    oral and periodontal health. The Indian clinical trial involved 28 adult
    volunteers with moderate to severe periodontitis. The results demonstrated
    that the sub-group of participants taking the probiotic BLIS M18 lozenges for
    one month recorded statistically significant improvements in multiple indices
    of periodontal health. The research has recently been published in the
    International Journal of Pharma and Bio Science.
    In commenting, the Chief Executive of BLIS Technologies, Dr Barry Richardson,
    noted that this independent study provided further evidence of the
    effectiveness of BLIS M18 in improving periodontal health. The study authors
    summarized their findings by stating that "Streptococcus salivarius M18 may
    be potentially useful as an aid in improving the oral health of periodontal
    BLIS M18 is a member of the bacterial species Streptococcus salivarius
    originally developed by BLIS Technologies Ltd in Dunedin, New Zealand for the
    support of oral health. One aspect of the probiotic's mechanism of action is
    the production of multiple bacteriocins (naturally produced substances) that
    selectively inhibit the growth of oral pathogens involved in the development
    of dental caries including Streptococcus mutans.
    Reference: Scariya, L et al (2015). Int J Pharm Bio Sci 6(1): 242 - 250
    BLIS Technologies Ltd supplied the BLIS M18 lozenges used by the researchers
    in this study.
    For further comment contact:
    Barry Richardson       021 664 742
    End CA:00260190 For:BLT    Type:GENERAL    Time:2015-02-02 08:30:07

Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.


Thank you for visiting HotCopper

We have detected that you are running ad blocking software.

HotCopper relies on revenue generated from advertisers. Kindly disable your ad blocking software to return to the HotCopper website.

I understand, I have disabled my ad blocker. Let me in!

Need help? Click here for support.